The risks of continuing to smoke after diagnosis, treatment for prostate cancer

An article just published in BJU International has further confirmed the risks associated with continuing to smoke cigarettes after initial diagnosis with, and treatment for, prostate cancer. … READ MORE …

Prediction of the “real” risk of death from prostate cancer

A while ago now we first discussed research being done by Eric Feuer and others on what was initially being called the Cancer Survival Query System or CSQS. … READ MORE …

First and second biopsies and their diagnostic accuracy

A paper by Wong et al. published in December carries the title, “Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.” … READ MORE …

PSA levels and eligibility for active surveillance

The general rule has been that only men with low-risk prostate cancer are suitable as possible candidates for active surveillance. Low risk is defined as a PSA < 10 ng/ml; a Gleason score of ≤ 6; and a clinical stage of ≤ T2aN0M0. … READ MORE …

To screen or not to screen: an Australian “discrete choice experiment”

The question of whether men should be regularly screened for risk of prostate cancer through the use of the PSA test is (at least) controversial … READ MORE …

Low detectable PSA after prostatectomy – watch or treat?

In a previous article, we looked at evidence that a low detectable level of PSA predicts eventual biochemical recurrence (a confirmed PSA greater than 0.2 ng/ml) when there is aggressive pathology. … READ MORE …

The value of the PCA3 test: a multi-center study

The prostate cancer antigen 3 or PCA3 test was initially approved as an aid to the assessment of risk of prostate cancer in men with an elevated PSA level who had already been given at least one prior, negative biopsy. … READ MORE ..

Follow

Get every new post delivered to your Inbox.

Join 1,211 other followers